Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics, Inc. (DNTH)
:DNTH
DNTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.37 - $32.27
Previous CloseN/A
Volume29.07K
Average Volume (3M)371.79K
Market Cap
$852.99M
Enterprise Value$411.31M
Total Cash (Recent Filing)$257.39M
Total Debt (Recent Filing)$1.33M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 06, 2025EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding32,188,347
10 Day Avg. Volume374,941
30 Day Avg. Volume371,791
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue84.74
Enterprise Value/Gross Profit86.50
Enterprise Value/Ebitda-3.17
Forecast
1Y Price Target
$53.29Price Target Upside101.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentDNTH103's mechanism of action and extended dosing interval is seen as a competitive advantage compared to other treatments.
Financial StabilityDianthus had approximately $309.1M in cash, cash equivalents, and investments, which is believed to be sufficient to fund planned operations into 2H27, providing a solid financial foundation.
Market OpportunityGMG is a large and growing commercial opportunity.
Bears Say
Financial PerformanceThe company reported license revenue for 2Q25 significantly below consensus estimates, which could raise concerns about short-term financial performance.
Short InterestShort Interest (% Float) 27.3%.
Stock RiskShould DNTH103 fall short in efficacy, there is a potential downside risk to the stock price.
Dianthus Therapeutics News
DNTH FAQ
What was Dianthus Therapeutics, Inc.’s price range in the past 12 months?
Dianthus Therapeutics, Inc. lowest stock price was $13.37 and its highest was $32.27 in the past 12 months.
What is Dianthus Therapeutics, Inc.’s market cap?
Dianthus Therapeutics, Inc.’s market cap is $852.99M.
When is Dianthus Therapeutics, Inc.’s upcoming earnings report date?
Dianthus Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 59 days.
How were Dianthus Therapeutics, Inc.’s earnings last quarter?
Dianthus Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.872 by -$0.008.
Is Dianthus Therapeutics, Inc. overvalued?
According to Wall Street analysts Dianthus Therapeutics, Inc.’s price is currently Undervalued.
Does Dianthus Therapeutics, Inc. pay dividends?
Dianthus Therapeutics, Inc. does not currently pay dividends.
What is Dianthus Therapeutics, Inc.’s EPS estimate?
Dianthus Therapeutics, Inc.’s EPS estimate is -0.9.
How many shares outstanding does Dianthus Therapeutics, Inc. have?
Dianthus Therapeutics, Inc. has 32,188,347 shares outstanding.
What happened to Dianthus Therapeutics, Inc.’s price movement after its last earnings report?
Dianthus Therapeutics, Inc. reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.872. Following the earnings report the stock price went down -2.037%.
Which hedge fund is a major shareholder of Dianthus Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DNTH
Dianthus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.29 (101.09% Upside)
$53.29 (101.09% Upside)
Blogger Sentiment
Bullish
DNTH Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 896.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.28%
12-Months-Change
Fundamentals
Return on Equity
-34.71%
Trailing 12-Months
Asset Growth
-11.62%
Trailing 12-Months
Company Description
Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
DNTH Stock 12 Month Forecast
Average Price Target
$53.29
▲(101.09% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
AnaptysBio
―
Trevi Therapeutics
―
Immunome
―
Pharming Group
―
Ownership Overview
8.41% Insiders
16.49% Mutual Funds
<0.01% Other Institutional Investors
66.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---